After Reaching Milestone, Is Insmed Inc (NASDAQ:INSM)’s Short Interest Revealing Something?

Insmed Incorporated (NASDAQ:INSM) Logo

Investors sentiment increased to 2.07 in 2019 Q2. Its up 0.17, from 1.9 in 2019Q1. It increased, as 15 investors sold Insmed Incorporated shares while 29 reduced holdings. 30 funds opened positions while 61 raised stakes. 117.60 million shares or 52.97% more from 76.88 million shares in 2019Q1 were reported.
Consonance Mngmt Lp reported 1.71M shares or 3.1% of all its holdings. Tiverton Asset Mngmt Ltd Limited Liability Company holds 0.02% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 23,416 shares. Parametric Associates, a Washington-based fund reported 93,116 shares. Strs Ohio owns 500 shares or 0% of their US portfolio. Alliancebernstein Lp stated it has 0% in Insmed Incorporated (NASDAQ:INSM). Ubs Oconnor Limited Liability Company stated it has 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Trexquant Investment Ltd Partnership holds 37,806 shares. Adage Capital Ptnrs Gru Ltd Liability owns 199,000 shares for 0.01% of their portfolio. New York-based Amer Intll has invested 0.01% in Insmed Incorporated (NASDAQ:INSM). 86,623 are owned by Wells Fargo Mn. Fmr Ltd Llc invested in 0.03% or 10.59 million shares. Gardner Lewis Asset Ltd Partnership reported 107,210 shares. Nicholas Inv Prtn Lp has invested 0.37% of its portfolio in Insmed Incorporated (NASDAQ:INSM). New Jersey-based Prudential Fincl Incorporated has invested 0% in Insmed Incorporated (NASDAQ:INSM). Mackay Shields Limited Liability Company holds 66,180 shares.

The stock of Insmed Inc (NASDAQ:INSM) registered an increase of 5.76% in short interest. INSM’s total short interest was 12.20M shares in September as published by FINRA. Its up 5.76% from 11.53M shares, reported previously. With 988,500 shares average volume, it will take short sellers 12 days to cover their INSM’s short positions.

The stock decreased 1.00% or $0.19 during the last trading session, reaching $18.82. About 543,625 shares traded. Insmed Incorporated (NASDAQ:INSM) has declined 9.30% since September 13, 2018 and is downtrending. It has underperformed by 9.30% the S&P500.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.68 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 2 analysts covering Insmed (NASDAQ:INSM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insmed has $43 highest and $3000 lowest target. $36.50’s average target is 93.94% above currents $18.82 stock price. Insmed had 3 analyst reports since March 26, 2019 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, March 26.

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: which released: “Insmed closes stock offering – Seeking Alpha” on June 27, 2019, also with their article: “Insmed Inc (INSM) Chairman, President & CEO William Lewis Sold $10.4 million of Shares – Yahoo Finance” published on June 25, 2019, published: “Insider Bets Paying Off At INSM As New 52-Week High Reached – Nasdaq” on April 08, 2019. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: and their article: “Here’s Why Insmed Fell Hard Today – Nasdaq” published on August 01, 2019 as well as‘s news article titled: “Insmed Q2 2019 Earnings Preview – Seeking Alpha” with publication date: July 31, 2019.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.